For Rare, Difficult Cancer, New Drug Is a ' Major Advance ' For Rare, Difficult Cancer, New Drug Is a ' Major Advance '

Tagraxofusp, the first-ever drug for blastic plasmacytoid dendritic-cell neoplasm, is being called a major advance. Data are now published in the New England Journal of Medicine.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news